Halozyme Therapeutics (HALO) in Focus: Stock Up 6.4%
Halozyme Therapeutics, Inc. HALO was a big mover last session, as the company saw its shares rise above 6% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $9.88 to $12.61 in the past one-month time frame.
In the last 30 days, the company has seen no estimate revision and the Zacks Consensus Estimate also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Halozyme Therapeutics currently carries a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
Halozyme Therapeutics, Inc. Price
Halozyme Therapeutics, Inc. Price | Halozyme Therapeutics, Inc. Quote
A better-ranked Medical-Biomedical and Genetics stock is Enzo Biochem, Inc. ENZ, which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is HALO going up? Or down? Predict to see what others think: Up or Down
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017? Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report
Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report
To read this article on Zacks.com click here.
